Portal:CPTAC/Hallmark/Proliferative
From WikiPathways
(Difference between revisions)
Current revision (00:11, 11 October 2019) (view source) (removed main pathway models) |
|||
| (17 intermediate revisions not shown.) | |||
| Line 1: | Line 1: | ||
| - | *[[Pathway:WP673]] | + | The normal control of cell growth and division in cells is governed by careful control and release of growth-promoting signals, but in cancer cells this control is deregulated. |
| - | *[[Pathway: | + | Signaling through growth factors via the tyrosine kinase domains of cell-surface receptors, trigger progression through the cell cycle and other pathways. (Adapted from [https://www.ncbi.nlm.nih.gov/pubmed/21376230 Hallmarks of cancer: the next generation, Hanahan and Weinberg, Cell 2011]) |
| - | *[[Pathway: | + | *[[Pathway:WP3972]] PDGFR-beta pathway |
| - | *[[Pathway: | + | *[[Pathway:WP673]] ErbB Signaling Pathway |
| - | *[[Pathway: | + | *[[Pathway:WP581]] EPO Receptor Signaling |
| - | *[[Pathway: | + | *[[Pathway:WP382]] MAPK Signaling Pathway |
| - | *[[Pathway: | + | *[[Pathway:WP4223]] Ras Signaling |
| - | *[[Pathway: | + | *[[Pathway:WP4205]] MET in type 1 papillary renal cell carcinoma |
| + | *[[Pathway:WP313]] Signaling of Hepatocyte Growth Factor Receptor | ||
| + | *[[Pathway:WP4553]] FBXL10 enhancement of MAP/ERK signaling in diffuse large B-cell lymphoma | ||
| + | *[[Pathway:WP4566]] Translation inhibitors in chronically activated PDGFRA cells | ||
| + | *[[Pathway:WP4541]] Hippo-Merlin Signaling Dysregulation | ||
Current revision
The normal control of cell growth and division in cells is governed by careful control and release of growth-promoting signals, but in cancer cells this control is deregulated. Signaling through growth factors via the tyrosine kinase domains of cell-surface receptors, trigger progression through the cell cycle and other pathways. (Adapted from Hallmarks of cancer: the next generation, Hanahan and Weinberg, Cell 2011)
- Pathway:WP3972 PDGFR-beta pathway
- Pathway:WP673 ErbB Signaling Pathway
- Pathway:WP581 EPO Receptor Signaling
- Pathway:WP382 MAPK Signaling Pathway
- Pathway:WP4223 Ras Signaling
- Pathway:WP4205 MET in type 1 papillary renal cell carcinoma
- Pathway:WP313 Signaling of Hepatocyte Growth Factor Receptor
- Pathway:WP4553 FBXL10 enhancement of MAP/ERK signaling in diffuse large B-cell lymphoma
- Pathway:WP4566 Translation inhibitors in chronically activated PDGFRA cells
- Pathway:WP4541 Hippo-Merlin Signaling Dysregulation
